Dr. Anna Bigas, among the "Top 100 Women Leaders"
The Deputy Director of Preclinical Research at the Josep Carreras Leukemia Research Institute and head of the Stem Cells and Cancer group, based at the Hospital del Mar - IMIM campus, has been selected as one of the 100 most outstanding women leaders in Spain.
On April 21 in the afternoon, the digital magazine Mujeres & Cia. Organized the annual gala to announce the top 100 women in the "Top 100 Women Leaders" ranking. The event, with a hybrid format, on-site and virtual, was conducted by the journalist, television presenter and writer Sonsoles Ónega and was attended by the Second Vice President of the Government, Nadia Calviño, and the special performance of the soprano Pilar Jurado.
In this ninth edition, more than 500 candidates, distributed in 10 categories ranging from senior business management to scientific research, received more than 75,000 votes from 32,000 voters, establishing a new participation record.
Precisely in this last category, "academics, scientists and thinkers", Dr. Anna Bigas, Deputy Director of Preclinical Research at the Josep Carreras Institute and head of the Stem Cells and Cancer group at the Hospital del Mar Medical Research Institute (IMIM) was awarded. Dr. Bigas was selected for her scientific work at the head of CIBERONC, the thematic area dedicated to the study of cancer of the Centro de Investigación Biomédica en Red (CIBER) of the Instituto de Salud Carlos III (ISCIII).
Dr. Bigas's research is focused on understanding how hematopoietic stem cells, responsible for the formation of the rest of the blood cells, are formed and regenerated and how the alteration of their normal functioning can lead to cancer onset. This knowledge is key in the fight against blood diseases, such as leukemia or lymphomas.
In addition to directing the CIBERONC, Dr. Bigas enjoys a great international projection and is part of the direction of the International Society of Experimental Hematology (ISEH), is a member of the Asociación Española de Hematología y Hemoterapia (AEHH), the European Hematology Association (EHA) and the Asociación Española de Investigación sobre el Cáncer (ASEICAR). Due to her international relevance, she serves as a reviewer for the European Research Council (ERC) and the Research Councils of Finland and Lithuania. In addition, she occasionally serves as a reviewer for the Norwegian Research Council, the UK Medical Research Council, the French National Research Agency and the Israel Ministry of Science.